Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Zur Rose Group AG
  6. Summary
    ROSE   CH0042615283

ZUR ROSE GROUP AG

(ROSE)
  Report
Real-time Estimate Quote. Real-time Estimate Cboe Europe - 01/27 07:43:56 am
206 CHF   +5.42%
05:15aZUR ROSE GROUP : Warburg Research reiterates its Buy rating
MD
01/26ZUR ROSE GROUP : Buy rating from Jefferies
MD
01/24ZUR ROSE GROUP : UBS maintains a Sell rating
MD
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
01/21/2022 01/24/2022 01/25/2022 01/26/2022 01/27/2022 Date
202(c) 174(c) 175.2(c) 195.4(c) 206 Last
135 306 217 844 102 369 151 626 108 885 Volume
+0.50% -13.86% +0.69% +11.53% +5.42% Change
More quotes
Estimated financial data (e)
Sales 2021 1 744 M 1 880 M 1 880 M
Net income 2021 -192 M -207 M -207 M
Net Debt 2021 316 M 340 M 340 M
P/E ratio 2021 -10,6x
Yield 2021 -
Sales 2022 2 114 M 2 279 M 2 279 M
Net income 2022 -144 M -155 M -155 M
Net Debt 2022 467 M 503 M 503 M
P/E ratio 2022 -14,7x
Yield 2022 -
Capitalization 2 001 M 2 171 M 2 157 M
EV / Sales 2021 1,33x
EV / Sales 2022 1,17x
Nbr of Employees 1 960
Free-Float 88,3%
More Financials
Company
Zur Rose Group AG is a Switzerland-based company engaged in the drug distribution sector. The Company focuses on the wholesale trade of medicines, as well as operation of a mail-order pharmacy. The Company's activities are divided into two business segments: Zur Rose and DocMorris. The Zur Rose division includes wholesale business and provides drugs to medical doctors, health insurance companies, hospitals and... 
Sector
Drug Retailers
Calendar
03/24Earnings Release
More about the company
Ratings of Zur Rose Group AG
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about ZUR ROSE GROUP AG
05:15aZUR ROSE GROUP : Warburg Research reiterates its Buy rating
MD
01/26ZUR ROSE GROUP : Buy rating from Jefferies
MD
01/24ZUR ROSE GROUP : UBS maintains a Sell rating
MD
01/24ZUR ROSE GROUP : Berenberg reaffirms its Neutral rating
MD
01/21AlphaValue/Baader Europe Lifts Price Target on Galenica, Maintains Add Recommendation
MT
01/21ZUR ROSE GROUP : UBS gives a Sell rating
MD
01/20European Stocks Close Broadly Higher Amid Rising Inflation
MT
01/20Global markets live: Unilever, United Airlines, Amazon, Walt Disney, Novavax...
01/20ZUR ROSE GROUP : Jefferies gives a Buy rating
MD
01/20ZUR ROSE GROUP : Warburg Research reaffirms its Buy rating
MD
01/20Switzerland's Zur Rose Group Logs 17% Revenue Growth In FY21
MT
01/20ZUR ROSE GROUP : steady growth in a volatile market environment
EQ
01/20Zur Rose Group AG Announces Unaudited Revenue Results for Fourth Quarter and Year Ended..
CI
01/19Zur Rose's Online Shopping Site Hit with Cyberattack
MT
01/19ZUR ROSE : Release December 2021
PU
More news
News in other languages on ZUR ROSE GROUP AG
07:31aAKTIEN IM FOKUS : Online-Apotheken profitieren weiter von neuem eRezept-Fahrplan
04:39aZUR ROSE : Aucune donnée concernant la boutique en ligne de produits cosmétiques et de soi..
04:39aZUR ROSE : Keine Datenentwendung beim Online-Shop für Kosmetik- und Körperpflegeprodukte z..
01/26Zur Rose-Aktie von Fortschritten beim deutschen E-Rezept beflügelt
01/26AKTIEN EUROPA SCHLUSS : Erholung gewinnt vor Fed-Entscheid an Schwung
More news
Analyst Recommendations on ZUR ROSE GROUP AG
More recommendations
Chart ZUR ROSE GROUP AG
Duration : Period :
Zur Rose Group AG Technical Analysis Chart | ROSE | CH0042615283 | MarketScreener
Technical analysis trends ZUR ROSE GROUP AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Last Close Price 195,40 CHF
Average target price 327,30 CHF
Spread / Average Target 67,5%
EPS Revisions
Managers and Directors
Walter Oberhänsli Chief Executive Officer & Executive Director
Marcel Ziwica Chief Financial Officer
Stefan Feuerstein Chairman
Madhu Nutakki Chief Technology Officer
Bernd Michael Gschaider Chief Operating Officer
Sector and Competitors